Faecal chitinase 3-like-1: A novel biomarker of disease activity in paediatric inflammatory bowel disease

Alimentary Pharmacology and Therapeutics

Volumn 34, Issue 8, 2011, Pages 941-948

  Aomatsu, T ^a,b   Imaeda, H ^a   Matsumoto, K ^c   Kimura, E ^c   Yoden, A ^b   Tamai, H ^b   Fujiyama, Y ^a   Mizoguchi, E ^d   Andoh, A ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b OSAKA MEDICAL COLLEGE   (Japan)

^c Mikuri Immunological Lab Co   (Japan)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALGRANULIN; CHITINASE LIKE 1 PROTEIN; CORTICOSTEROID; MERCAPTOPURINE; MESALAZINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHILD HEALTH; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; CORRELATIONAL STUDY; CROHN DISEASE; DISEASE SEVERITY; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FECES ANALYSIS; GASTROINTESTINAL ENDOSCOPY; HUMAN; ILEUM DISEASE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MATTS SCORE; MOUSE; NONHUMAN; PEDIATRIC CROHN DISEASE ACTIVITY INDEX; PEDIATRIC ULCERATIVE COLITIS DISEASE ACTIVITY INDEX; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; SIMPLE ENDOSCOPIC SCORE FOR CROHN DISEASE; ULCERATIVE COLITIS; UPREGULATION;

ADIPOKINES; ADOLESCENT; BIOLOGICAL MARKERS; CHILD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FECES; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; LECTINS; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; SEVERITY OF ILLNESS INDEX;

EID: 80053188757     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04805.x     Document Type: Article

References (42)

1. Podolsky DK,. Inflammatory bowel disease. N Engl J Med 2002; 347: 417-29. (Pubitemid 34851835)
2. Mizoguchi A, Mizoguchi E,. Inflammatory bowel disease, past, present and future: lessons from animal models. J Gastroenterol 2008; 43: 1-17. (Pubitemid 351324980)
3. Sartor RB,. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 390-407. (Pubitemid 44018812)
4. Kobori A, Yagi Y, Imaeda H, et al. Interleukin-33 expression is specifically enhanced in inflamed mucosa of ulcerative colitis. J Gastroenterol 2010; 45: 999-1007.
5. Mayer L,. Evolving paradigms in the pathogenesis of IBD. J Gastroenterol 2010; 45: 9-16.
6. Debono M, Gordee RS,. Antibiotics that inhibit fungal cell wall development. Annu Rev Microbiol 1994; 48: 471-97. (Pubitemid 24334106)
7. Zhu Z, Zheng T, Homer RJ, et al. Acidic mammalian chitinase in asthmatic Th2 inflammation and IL-13 pathway activation. Science 2004; 304: 1678-82. (Pubitemid 38765861)
8. Wills-Karp M, Karp CL,. Chitin checking-novel insights into asthma. N Engl J Med 2004; 351: 1455-7.
9. Kawada M, Chen CC, Arihiro A, Nagatani K, Watanabe T, Mizoguchi E,. Chitinase 3-like-1 enhances bacterial adhesion to colonic epithelial cells through the interaction with bacterial chitin-binding protein. Lab Invest 2008; 88: 883-95.
10. Chen CC, Llado V, Eurich K, Tran HT, Mizoguchi E,. Carbohydrate-binding motif in chitinase 3-like 1 (CHI3L1/YKL-40) specifically activates Akt signaling pathway in colonic epithelial cells. Clin Immunol 2011 [Epub ahead of print].
11. Mizoguchi E,. Chitinase 3-like-1 exacerbates intestinal inflammation by enhancing bacterial adhesion and invasion in colonic epithelial cells. Gastroenterology 2006; 130: 398-411. (Pubitemid 43202039)
12. Cabrera-Abreu JC, Davies P, Matek Z, Murphy MS,. Performance of blood tests in diagnosis of inflammatory bowel disease in a specialist clinic. Arch Dis Child 2004; 89: 69-71. (Pubitemid 38122017)
13. Mack DR, Langton C, Markowitz J, et al. Laboratory values for children with newly diagnosed inflammatory bowel disease. Pediatrics 2007; 119: 1113-9. (Pubitemid 46871266)
14. Quail MA, Russell RK, Van Limbergen JE, et al. Fecal calprotectin complements routine laboratory investigations in diagnosing childhood inflammatory bowel disease. Inflamm Bowel Dis 2009; 15: 756-9.
15. Vieira A, Fang CB, Rolim EG, et al. Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes. BMC Res Notes 2009; 2: 221.
16. Beattie RM, Walker-Smith JA, Murch SH,. Indications for investigation of chronic gastrointestinal symptoms. Arch Dis Child 1995; 73: 354-5.
17. Gisbert JP, McNicholl AG,. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Dig Liver Dis 2009; 41: 56-66.
18. Kaiser T, Langhorst J, Wittkowski H, et al. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome. Gut 2007; 56: 1706-13. (Pubitemid 350206297)
19. Foell D, Wittkowski H, Roth J,. Monitoring disease activity by stool analyses: from occult blood to molecular markers of intestinal inflammation and damage. Gut 2009; 58: 859-68.
20. Desai D, Faubion WA, Sandborn WJ,. Review article: biological activity markers in inflammatory bowel disease. Aliment Pharmacol Ther 2007; 25: 247-55. (Pubitemid 46115394)
21. Limburg PJ, Ahlquist DA, Sandborn WJ, et al. Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy. Am J Gastroenterol 2000; 95: 2831-7.
22. Ashorn S, Honkanen T, Kolho KL, et al. Fecal calprotectin levels and serological responses to microbial antigens among children and adolescents with inflammatory bowel disease. Inflamm Bowel Dis 2009; 15: 199-205.
23. Sipponen T, Savilahti E, Karkkainen P, et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. Inflamm Bowel Dis 2008; 14: 1392-8.
24. Sipponen T, Karkkainen P, Savilahti E, et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Aliment Pharmacol Ther 2008; 28: 1221-9.
25. Gaya DR, Lyon TD, Duncan A, et al. Faecal calprotectin in the assessment of Crohn's disease activity. QJM 2005; 98: 435-41. (Pubitemid 40796815)
26. Dale I, Fagerhol MK, Naesgaard I,. Purification and partial characterization of a highly immunogenic human leukocyte protein, the L1 antigen. Eur J Biochem 1983; 134: 1-6. (Pubitemid 13051561)
27. Foell D, Wittkowski H, Ren Z, et al. Phagocyte-specific S100 proteins are released from affected mucosa and promote immune responses during inflammatory bowel disease. J Pathol 2008; 216: 183-92.
28. Houston DR, Recklies AD, Krupa JC, van Aalten DM,. Structure and ligand-induced conformational change of the 39-kDa glycoprotein from human articular chondrocytes. J Biol Chem 2003; 278: 30206-12. (Pubitemid 36962414)
29. Fusetti F, Pijning T, Kalk KH, Bos E, Dijkstra BW,. Crystal structure and carbohydrate-binding properties of the human cartilage glycoprotein-39. J Biol Chem 2003; 278: 37753-60. (Pubitemid 37175301)
30. Turner D, Otley AR, Mack D, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology 2007; 133: 423-32. (Pubitemid 47193130)
31. Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr 1991; 12: 439-47.
32. Matts SG,. The value of rectal biopsy in the diagnosis of ulcerative colitis. Q J Med 1961; 30: 393-407.
33. Osada T, Ohkusa T, Yokoyama T, et al. Comparison of several activity indices for the evaluation of endoscopic activity in UC: inter-and intraobserver consistency. Inflamm Bowel Dis 2010; 16: 192-7.
34. Satsangi J, Silverberg MS, Vermeire S, Colombel JF,. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006; 55: 749-53. (Pubitemid 43764536)
35. Daperno M, D'Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc 2004; 60: 505-12. (Pubitemid 39311530)
36. Minderhoud IM, Samsom M, Oldenburg B,. What predicts mucosal inflammation in Crohn's disease patients? Inflamm Bowel Dis 2007; 13: 1567-72.
37. Puylaert JB,. Ultrasonography of the acute abdomen: gastrointestinal conditions. Radiol Clin North Am 2003; 41: 1227-42. (Pubitemid 37490459)
38. Sturm EJ, Cobben LP, Meijssen MA, van der Werf SD, Puylaert JB,. Detection of ileocecal Crohn's disease using ultrasound as the primary imaging modality. Eur Radiol 2004; 14: 778-82. (Pubitemid 38678895)
39. Vind I, Johansen JS, Price PA, Munkholm P,. Serum YKL-40, a potential new marker of disease activity in patients with inflammatory bowel disease. Scand J Gastroenterol 2003; 38: 599-605. (Pubitemid 36724038)
40. Mizoguchi E, Mizoguchi A,. Is the sugar always sweet in intestinal inflammation? Immunol Res 2007; 37: 47-60. (Pubitemid 46742283)
41. Cintin C, Johansen JS, Christensen IJ, Price PA, Sorensen S, Nielsen HJ,. High serum YKL-40 level after surgery for colorectal carcinoma is related to short survival. Cancer 2002; 95: 267-74. (Pubitemid 34787591)
42. Lee CG, Hartl D, Lee GR, et al. Role of breast regression protein 39 (BRP-39)/chitinase 3-like-1 in Th2 and IL-13-induced tissue responses and apoptosis. J Exp Med 2009; 206: 1149-66.